Shilpa Medicare (SHILPAMED) Fundamentals 2026 — P/E 49.3x, Revenue Analysis | SniperIQ
Shilpa Medicare (SHILPAMED) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹5,999 Crore, trading at ₹613.45 on the BSE. This SniperIQ fundamentals page covers Shilpa Medicare's valuation (P/E 49.3x, P/B 4.6x), profitability (net margin 15.8%), revenue (₹1,539 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shilpa Medicare's market cap?
Shilpa Medicare (SHILPAMED) has a market capitalization of approximately ₹5,999 Crore, trading at ₹613.45 on the BSE. Market cap moves with the live share price.
What is Shilpa Medicare's P/E ratio?
Shilpa Medicare's trailing twelve-month P/E ratio is 49.3x, with a price-to-book (P/B) of 4.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shilpa Medicare?
Shilpa Medicare runs a net profit margin of 15.8%, a gross margin of 55.0%, and an operating margin of 20.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shilpa Medicare generate?
Shilpa Medicare reported revenue of ₹1,539 Crore for fiscal year 2026, with net income of ₹243 Crore and earnings per share (EPS) of 12.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shilpa Medicare pay a dividend?
Shilpa Medicare offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shilpa Medicare financially healthy?
Shilpa Medicare carries a debt-to-equity ratio of 0.25x and a current ratio of 1.31x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shilpa Medicare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shilpa Medicare (SHILPAMED) the key facts are: market cap ₹5,999 Crore, P/E 49.3x, revenue ₹1,539 Crore, 52-week range 260-650. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shilpa Medicare's full fundamentals live
Get Shilpa Medicare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.